Increased CSF levels of CXCL13 correlate with disease exacerbations and unfavourable prognosis in RRMS, whilst high levels predict conversion from a clinically isolated syndrome (CIS) to definitive MS [21], [22]. This evidence concerns the gene CXCL13 and myeloid sarcoma.